Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Sell
14
MBRX Quote, Financials, Valuation and Earnings
Last price:
$7.19
Seasonality move
:
-20.11%
Day range:
$6.88 - $7.69
52-week range:
$6.01 - $91.25
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
485.33x
Volume:
79.3K
Avg. volume:
182.8K
1-year change:
-88.42%
Market cap:
$15M
Revenue:
--
EPS (TTM):
-$43.94
Analysts' Opinion
-
Consensus RatingMoleculin Biotech, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $6.67, Moleculin Biotech, Inc. has an estimated upside of 2202.03% from its current price of $7.24.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $4.00 representing 100% downside risk from its current price of $7.24.
Fair Value
-
According to the consensus of 2 analysts, Moleculin Biotech, Inc. has 2202.03% upside to fair value with a price target of $6.67 per share.
MBRX vs. S&P 500
-
Over the past 5 trading days, Moleculin Biotech, Inc. has overperformed the S&P 500 by 5.87% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Moleculin Biotech, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Moleculin Biotech, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Moleculin Biotech, Inc. reported revenues of --.
Earnings Growth
-
Moleculin Biotech, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Moleculin Biotech, Inc. reported earnings per share of -$17.02.
Enterprise value:
8.7M
EV / Invested capital:
-0.33x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.39x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$112K
Return On Assets:
-213.6%
Net Income Margin (TTM):
--
Return On Equity:
-552.21%
Return On Invested Capital:
-502.35%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$231K | -$129K | -$112K | -$31K | -$21K | |
| Operating Income | -$27.8M | -$28.9M | -$24.2M | -$7.1M | -$5.9M | |
| EBITDA | -$27.5M | -$28.8M | -$24.1M | -$7.1M | -$5.9M | |
| Diluted EPS | -$13.52 | -$56.12 | -$43.94 | -$47.28 | -$17.02 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $77.1M | $53.5M | $27.6M | $5.2M | $7.9M | |
| Total Assets | $88.7M | $65.4M | $39.5M | $16.9M | $20.4M | |
| Current Liabilities | $3.7M | $6.4M | $3.9M | $5.4M | $5.7M | |
| Total Liabilities | $7.4M | $7M | $4.4M | $5.7M | $47.3M | |
| Total Equity | $81.3M | $58.4M | $35.1M | $11.2M | -$26.9M | |
| Total Debt | $75K | $365K | $496K | $358K | $258K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$26M | -$24.2M | -$22.5M | -$6.1M | -$7.2M | |
| Cash From Investing | -$43K | -$94K | -- | -- | -- | |
| Cash From Financing | $186K | $9.1M | $19.8M | $4.7M | $6.4M | |
| Free Cash Flow | -$26M | -$24.3M | -$22.5M | -$6.1M | -$7.2M | |
MBRX
Sector
Market Cap
$15M
$28.5M
Price % of 52-Week High
7.93%
51.44%
Dividend Yield
0%
0%
Shareholder Yield
-75.36%
-1.33%
1-Year Price Total Return
-88.42%
-20.32%
Beta (5-Year)
1.582
0.520
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$7.32
200-day SMA
Sell
Level
$17.12
Bollinger Bands (100)
Sell
Level
9.35 - 15.61
Chaikin Money Flow
Sell
Level
-7.8M
20-day SMA
Sell
Level
$9.58
Relative Strength Index (RSI14)
Sell
Level
32.37
ADX Line
Sell
Level
22.29
Williams %R
Neutral
Level
-77.4739
50-day SMA
Sell
Level
$11.17
MACD (12, 26)
Sell
Level
-1.26
25-day Aroon Oscillator
Sell
Level
-76
On Balance Volume
Neutral
Level
16.8M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-17.5773)
Sell
CA Score
(Annual)
Level (-4.4488)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (8.9794)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company. It engages in the business of growing a pipeline including phase 2 clinical programs for hard-to-treat cancers and viruses. The company was founded by Walter V. Klemp, Donald H. Picker, and Waldemar Priebe in July 2015 and is headquartered in Houston, TX.
Stock Forecast FAQ
In the current month, MBRX has received 2 Buy ratings 0 Hold ratings, and 0 Sell ratings. The MBRX average analyst price target in the past 3 months is $6.67.
-
Where Will Moleculin Biotech, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Moleculin Biotech, Inc. share price will rise to $6.67 per share over the next 12 months.
-
What Do Analysts Say About Moleculin Biotech, Inc.?
Analysts are divided on their view about Moleculin Biotech, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Moleculin Biotech, Inc. is a Sell and believe this share price will drop from its current level to $4.00.
-
What Is Moleculin Biotech, Inc.'s Price Target?
The price target for Moleculin Biotech, Inc. over the next 1-year time period is forecast to be $6.67 according to 2 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is MBRX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Moleculin Biotech, Inc. is a Buy. 2 of 2 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of MBRX?
You can purchase shares of Moleculin Biotech, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Moleculin Biotech, Inc. shares.
-
What Is The Moleculin Biotech, Inc. Share Price Today?
Moleculin Biotech, Inc. was last trading at $7.19 per share. This represents the most recent stock quote for Moleculin Biotech, Inc.. Yesterday, Moleculin Biotech, Inc. closed at $7.24 per share.
-
How To Buy Moleculin Biotech, Inc. Stock Online?
In order to purchase Moleculin Biotech, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get MBRX Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
MBRX
Sector
P/E ratio
--
23.75x
PEG ratio
--
-0.01x
P/B ratio
485.33x
1.83x
Price / LTM sales
--
1.60x
Growth Metrics
MBRX
Sector
Revenue growth
--
4.85%
Earnings growth
64%
11.11%
Revenue (5-year growth)
--
6.45%
Earnings forecast
--
-$0.20
Profitability
MBRX
Sector
Profitability FY 2024
-$126K
$3.6M
Return on invested capital
-502.35%
-30.98%
Return on assets
-213.6%
-27.62%
Return on equity
-552.21%
-36.69%
Earnings Date
Last Earnings Date
Aug
13
Next Earnings Date
Dec
8
Estimated Next Earnings Date
Mar
9
Balance Sheet
MBRX
Sector
Total cash
$6.7M
$27.2M
Short term investments
--
$25.7M
Total assets
$16.9M
$79.7M
Long term debt
$258K
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 8
SMX (Security Matters) Plc [SMX] is down 65.44% over the past day.
Buy
62
PRAX alert for Dec 8
Praxis Precision Medicines, Inc. [PRAX] is up 8.33% over the past day.
Sell
13
PSN alert for Dec 8
Parsons Corp. [PSN] is down 5.85% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
